Literature DB >> 18729822

Molecular imaging study on in vivo distribution and pharmacokinetics of modified small interfering RNAs (siRNAs).

Thomas Viel1, Raphael Boisgard, Bertrand Kuhnast, Benoit Jego, Karine Siquier-Pernet, Françoise Hinnen, Frédéric Dollé, Bertrand Tavitian.   

Abstract

Molecular imaging was used to study the biodistribution, pharmacokinetics, and activity of naked small interfering RNAs (siRNAs). siRNAs with riboses chemically modified in the 2' position were compared with unmodified siRNA. In vitro, replacement of the 2'-hydroxyl (2'OH) group of certain nucleotides in an siRNA sequence by a fluorine atom (2'F) on both antisense (AS) and sense (S) strands [2'F(AS/S)], or by a methoxy group (2'OMe) on the S strand [2'OH(AS)/2'OMe(S)], was compatible with RNA interference. Different siRNAs [2'F(AS/S), 2'OH(AS)/2'OMe(S), and 2'OH(AS/S)] were labeled with fluorine-18 (conjugation with [(18)F]FPyBrA), and comparative dynamic and quantitative imaging was performed with positron emission tomography. After intravenous injections of [(18)F]siRNAs in rodents, total radioactivity was rapidly eliminated by the kidneys and the liver. Tissue distribution of the different siRNAs were similar, and their bioavailability (as judged from blood persistence and stability) increased in the order 2'OH(AS/S) = 2'OH(AS)/2'OMe(S) < 2'F(AS/S). However, in our in vivo model, the 2'F(AS/S) siRNA, despite its higher bioavailability, was not able to induce a higher interference effect with respect to the 2'OH(AS/S) siRNA. Molecular imaging approaches, applied in the present work to both natural and chemically modified siRNAs, can contribute to the development of these macromolecules as therapeutic agents.

Mesh:

Substances:

Year:  2008        PMID: 18729822     DOI: 10.1089/oli.2008.0133

Source DB:  PubMed          Journal:  Oligonucleotides        ISSN: 1545-4576


  16 in total

1.  The effect of chemical modification and nanoparticle formulation on stability and biodistribution of siRNA in mice.

Authors:  Shan Gao; Frederik Dagnaes-Hansen; Ebbe Juel Bech Nielsen; Jesper Wengel; Flemming Besenbacher; Kenneth Alan Howard; Jørgen Kjems
Journal:  Mol Ther       Date:  2009-04-28       Impact factor: 11.454

2.  Unique gene-silencing and structural properties of 2'-fluoro-modified siRNAs.

Authors:  Muthiah Manoharan; Akin Akinc; Rajendra K Pandey; June Qin; Philipp Hadwiger; Matthias John; Kathy Mills; Klaus Charisse; Martin A Maier; Lubomir Nechev; Emily M Greene; Pradeep S Pallan; Eriks Rozners; Kallanthottathil G Rajeev; Martin Egli
Journal:  Angew Chem Int Ed Engl       Date:  2011-01-31       Impact factor: 15.336

Review 3.  The Race of 10 Synthetic RNAi-Based Drugs to the Pharmaceutical Market.

Authors:  Ricardo Titze-de-Almeida; Catherine David; Simoneide Souza Titze-de-Almeida
Journal:  Pharm Res       Date:  2017-04-07       Impact factor: 4.200

Review 4.  Progress toward in vivo use of siRNAs-II.

Authors:  Garrett R Rettig; Mark A Behlke
Journal:  Mol Ther       Date:  2011-12-20       Impact factor: 11.454

Review 5.  Multimodality imaging of RNA interference.

Authors:  T R Nayak; L K Krasteva; W Cai
Journal:  Curr Med Chem       Date:  2013       Impact factor: 4.530

Review 6.  Targeted delivery systems for oligonucleotide therapeutics.

Authors:  Bo Yu; Xiaobin Zhao; L James Lee; Robert J Lee
Journal:  AAPS J       Date:  2009-03-19       Impact factor: 4.009

Review 7.  In vivo imaging of RNA interference.

Authors:  Hao Hong; Yin Zhang; Weibo Cai
Journal:  J Nucl Med       Date:  2010-01-15       Impact factor: 10.057

Review 8.  Engineering RNA for targeted siRNA delivery and medical application.

Authors:  Peixuan Guo; Oana Coban; Nicholas M Snead; Joe Trebley; Steve Hoeprich; Songchuan Guo; Yi Shu
Journal:  Adv Drug Deliv Rev       Date:  2010-03-15       Impact factor: 15.470

9.  Optimizing glioblastoma temozolomide chemotherapy employing lentiviral-based anti-MGMT shRNA technology.

Authors:  Thomas Viel; Parisa Monfared; Sonja Schelhaas; Inga B Fricke; Michael T Kuhlmann; Cornel Fraefel; Andreas H Jacobs
Journal:  Mol Ther       Date:  2013-01-15       Impact factor: 11.454

10.  Self-assembled Micelle Interfering RNA for Effective and Safe Targeting of Dysregulated Genes in Pulmonary Fibrosis.

Authors:  Pyoung Oh Yoon; Jin Wook Park; Chang-Min Lee; Sung Hwan Kim; Han-Na Kim; Youngho Ko; Seon Joo Bae; Sungil Yun; Jun Hong Park; Taewoo Kwon; Woo Seok Kim; Jiyoung Lee; Qing Lu; Hye-Ryun Kang; Won-Kyung Cho; Jack A Elias; Joo-Sung Yang; Han-Oh Park; Kyuhong Lee; Chun Geun Lee
Journal:  J Biol Chem       Date:  2016-01-27       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.